Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Hepatocellular 19Stomach Neoplasms 12Colorectal Neoplasms 10Rectal Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Esophageal Squamous Cell Carcinoma 5Pancreatic Neoplasms 4Esophageal Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Neoplasm Metastasis 3Nasopharyngeal Carcinoma 3Lung Neoplasms 3Triple Negative Breast Neoplasms 2Endometrial Neoplasms 2Turcot syndrome 1Thyroid Neoplasms 1Squamous Cell Non-small Cell Lung Cancer 1Spinocerebellar Degenerations 1Sarcoma 1Salivary Gland Malignant Neoplasms 1Resectable NSCLC 1Recurrence 1Rare Tumor 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neuroblastoma 1Neoplasms 1NSCLC 1Microsatellite Stable Metastatic Colorectal Cancer 1Metastatic Gastroesophageal Junction Adenocarcinoma 1

Interventions

Temozolomide 16Irinotecan 13Cyclophosphamide 11dinutuximab 9naxitamab 7Vincristine 7Carboplatin 6sargramostim 5Melphalan 5Granulocyte-Macrophage Colony-Stimulating Factor 5Etoposide 5fludarabine 4Topotecan 4Thiotepa 4Eflornithine 4Doxorubicin 4Cisplatin 4etoposide phosphate 3Zoledronic Acid 3Specimen Handling 3Isotretinoin 3Granulocyte Colony-Stimulating Factor 3saponin QA-21V1 2lutetium Lu 177 dotatate 2aldesleukin 2Vorinostat 2Stem Cell Transplantation 2Radiation 2Platinum 2Mesna 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neuroblastoma × sintilimab × Clear all
NCT06013618 2025-06-17

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Sun Yat-sen University

Phase 2 Recruiting
120 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡